Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813108 | 1.00 | IDO1 (0.52) | IDO1HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL4669556 | 1.00 | IDO1 (0.52) | IDO1HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL17407618 | 0.85 | IDO1 (0.49) | IDO1HTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL320896 | 0.84 | IDO1 (0.50) | IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29049552 | 0.84 | IDO1 (0.55) | IDO1SLC6A2SLC6A4DPP4DPP7 | |
| SCHEMBL267012 | 0.81 | SLC6A2 (0.56) | IDO1SLC6A2SLC6A4SLC6A3DPP4 | |
| SCHEMBL15160740 | 0.81 | IDO1 (0.47) | IDO1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL30184157 | 0.81 | IDO1 (0.47) | IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2426168 | 0.81 | IDO1 (0.47) | IDO1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL28718967 | 0.81 | SLC6A2 (0.45) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| CN-116768737-A | Preparation method of interface passivation material and perovskite passivation layer | 武汉理工大学 | 2023-09-19 | — | — | CN | disclosed |
| EP-3829558-A1 | METHOD FOR TREATING EPILEPSY | Xenon Pharmaceuticals Inc. (CA) | 2021-06-09 | — | — | EP | disclosed |
| CN-112930175-A | Method for treating epilepsy | 泽农医药公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112830879-A | Preparation method of cinacalcet hydrochloride | 北京泰德制药股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| WO-2020023923-A1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC. (CA) | 2020-01-30 | — | — | WO | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-7169592-B2 | Producing optically active amino compounds | KANEKA CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-0857790-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | KANEKA CORP (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20020192786-A1 | Producing optically active amino compounds | KANEKA CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6346402-B1 | ACTS ON OPTICALLY ACTIVE (S)-ALPHA-PHENETHYLAMINE AND PYRUVIC ACID TO FORM ACETOPHENONE AND ALANINE; FOR PRODUCING CHEMICAL INTERMEDIATES OF DRUGS AND AGRICULTURAL CHEMICALS | KANEKA CORPORATION (JP) | 2002-02-12 | — | — | US | disclosed |
| US-6344351-B2 | USING (R)-FORM-SPECIFIC TRANSAMINASE WITH KETONE AMINO ACCEPTOR AND AMINO DONOR; ANTIDIABETES AND ANTIOBESITY AGENTS | KANEKA CORPORATION (JP) | 2002-02-05 | — | — | US | disclosed |
| US-20010031487-A1 | Process for producing optically active amino compounds | KANEKA CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6221638-B1 | BY STEREOSELECTIVELY CARRYING OUT AMINO GROUP TRANSFER BY ACTION OF AN (R)-FORM-SPECIFIC TRANSAMINASE IN THE CO-PRESENCE OF A KETONE (AMINO ACCEPTOR) AND AMINO COMPOUND (AMINO DONOR); YIELDS AMINO COMPOUNDS HAIVNG ARYL GROUP AT THE 1-POSITION | KANEKA CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-1045025-A1 | (S)-alpha-PHENETHYLAMINE : PYRUVATE TRANSAMINASE | KANEKA CORPORATION (JP) | 2000-10-18 | — | — | EP | disclosed |
| EP-0987332-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | Kaneka Corporation (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0857790-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | KANEKA CORPORATION (JP) | 1998-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | IDO1 1991/4885HTR2A 4707/4885HTR2C 4758/4885 |
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | PNMT, HTR5A, TPH1 | IDO1 434/4885HTR2A 9/4885HTR2C 16/4885 |
| US-20020192786-A1 | Producing optically active amino compounds | TKT, GOT1, AADAT | IDO1 1448/4885HTR2A 3443/4885HTR2C 4266/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | IDO1 2053/4885HTR2A 4699/4885HTR2C 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.